10-Q: Omada Health Q1 Revenue Soars 42%, Net Loss Narrows

Omada Health reports strong first-quarter revenue growth of 42% to $78 million, significantly reducing its net loss to $3 million, driven by a 51% increase in total members.

Summary

• Total revenue increased by 42% to $78.0 million for the three months ended March 31, 2026, up from $55.0 million in the prior-year period.
• Net loss significantly improved to $3.0 million in Q1 2026, compared to a net loss of $9.4 million in Q1 2025.
• Gross profit rose by 53% to $48.7 million, with gross margin expanding by 4.3 percentage points to 62.4%.
• Total members surpassed one million for the first time, reaching 1,025,000 as of March 31, 2026, a 51% increase year-over-year.
• Operating loss improved to $4.8 million from $8.4 million in the prior year.
• Cash and cash equivalents stood at $211.8 million as of March 31, 2026.
• The company continues to address a material weakness in internal control over financial reporting related to inadequate formalized processes and control activities.
• Management adopted Rule 10b5-1 trading arrangements for future stock sales by key executives.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, highlighting robust revenue growth and a substantial reduction in net loss, driven by strong member acquisition. However, continued unprofitability and reliance on key partners temper the overall sentiment.

Positives

• Total revenue increased by $23.1 million, or 42%, for the three months ended March 31, 2026, compared to the prior-year period.
• Net loss decreased by $6.5 million, or 68.6%, from $9.4 million in Q1 2025 to $3.0 million in Q1 2026.
• Gross profit increased by $16.8 million, or 53%, and gross margin expanded by 4.3 percentage points to 62.4%.
• Total members grew by 51% year-over-year, reaching 1,025,000 as of March 31, 2026, surpassing one million for the first time.
• Services revenue increased by 41% and hardware revenue increased by 55% year-over-year.
• Interest expense decreased by 98% due to the extinguishment of financing arrangements.
• Interest income increased by 237% to $1.8 million, primarily driven by interest earned from IPO proceeds.
• Improved Care Team efficiency and expanded use of supporting technologies contributed to gross margin expansion.
• The company announced the capability to prescribe GLP-1 therapies and other anti-obesity medications (AOMs), reflecting a proactive approach to evolving care models.

Negatives

• The company continues to incur net losses, with a net loss of $3.0 million for the quarter, and has an accumulated deficit of $459.7 million as of March 31, 2026.
• Operating expenses increased by 33% to $53.5 million, driven by higher personnel costs, administrative and marketing fees paid to channel partners, and technology infrastructure expenses.
• Net cash used in operating activities was $11.8 million for the three months ended March 31, 2026.
• Net cash used in investing activities increased to $1.6 million for the three months ended March 31, 2026.
• A substantial portion of sales (78% in Q1 2026) comes from or through a limited number of customers and channel partners, primarily affiliates of The Cigna Group, posing concentration risk.
• The business experiences seasonality, with higher new member enrollment in Q1 and Q2 leading to increased Care Team costs and lower overall gross margins in those quarters.

Risks

• The company has a limited operating history and faces challenges in effectively managing its rapid growth.
• A history of net losses indicates that consistent profitability may not be achieved in the future.
• Failure of programs to achieve and maintain market acceptance could result in sales below expectations.
• The virtual care market is new, rapidly evolving, and increasingly competitive, making demand forecasting difficult.
• Competition from existing or potential competitors, some with greater resources, could materially and adversely affect the business.
• Competitive solutions or technological breakthroughs for chronic conditions may adversely affect demand for programs.
• Business growth relies on the growth and success of customers and channel partners, which are difficult to predict and affected by external factors.
• A decrease in covered individuals or programs covered by customers/channel partners could lead to declining member enrollment and revenue.
• Revenue depends on member engagement, clinical outcomes, and cost savings; failure to meet targets could result in fee repayments.
• Significant upfront costs in establishing and expanding customer/channel partner relationships may not be recovered if relationships are not maintained or grown.
• A substantial portion of sales comes from or through a limited number of customers and channel partners, specifically affiliates of The Cigna Group.
• Inability to attract new customers/channel partners and increase member enrollment could slow revenue growth.
• The company needs to increase the size of its organization, including Care Teams, and may experience difficulties in managing growth and attracting talent.
• Programs may result in member harm or injury, potentially leading to liability claims.
• Dependence on a limited number of third-party suppliers for devices, cellular connectivity, and complementary healthcare services poses supply chain risks.
• Seasonality in business may cause fluctuations in financial results.
• Information technology (IT) systems and those of third-party service providers may fail or suffer cybersecurity incidents, data breaches, and other disruptions.
• Operating in a highly regulated industry means changes in regulations or their implementation could affect operations.
• Use and disclosure of personal information, including health information, is subject to federal and state privacy and security laws (e.g., HIPAA, CCPA), with non-compliance risks.
• Failure to comply with federal and state healthcare regulatory laws (e.g., Anti-Kickback Statute, Stark Law, False Claims Act) could lead to significant penalties.
• Legislative or regulatory healthcare reforms or reductions in government spending may make it more difficult and costly to produce, market, and distribute programs profitably.
• A previously identified material weakness in internal control over financial reporting related to inadequate formalized processes and control activities still exists and is undergoing remediation.
• Risks related to credit card and debit card payments, including compliance and fraud.
• The use of AI and machine learning technologies is subject to a rapidly changing regulatory landscape and potential performance issues.
• Failure to attract and retain senior leadership and key clinical, scientific, and technology employees could adversely affect the business.
• Reliance on a direct sales force means inability to maintain or expand it could impede growth.
• A decline in employer-sponsored healthcare could have a material adverse effect on the business.
• The sales and implementation cycle can be long and unpredictable, making sales and revenue difficult to forecast.
• Failure to offer high-quality support for customers, channel partners, and members may adversely affect relationships.
• Failure to develop widespread brand awareness cost-effectively or widespread negative media coverage could harm the business.
• Inability to develop and release new programs and services or successful enhancements to existing ones could adversely affect the business.
• Public opinion and scrutiny of treatments for obesity and overweight, particularly GLP-1s, may impact public perception of the company and its offerings.
• Expansion into international markets would introduce additional business, political, regulatory, operational, financial, and economic risks.
• Inability to successfully execute on growth initiatives, business strategies, or operating plans.
• Risk that licensed physical therapists are characterized as employees rather than independent contractors, affecting the business model.
• Any disruption of service at third-party data centers and hosting providers, including Amazon Web Services (AWS), could interrupt program delivery.
• Proprietary technology may not operate properly, damaging reputation or leading to claims.
• Business depends upon the interoperability of programs and related connected devices across a number of devices, operating systems, and third-party applications not controlled by the company.
• Dependence on continued and unimpeded access to Internet or mobile connections for programs and connected devices.
• Inability to obtain, maintain, or successfully enforce intellectual property rights could adversely affect commercial value and competitive position.
• Involvement in lawsuits to protect or enforce intellectual property rights could be expensive, time-consuming, and unsuccessful.
• Risk of infringing, misappropriating, or otherwise violating the intellectual property rights of third parties.
• Failure to comply with obligations under license or technology agreements with third parties could lead to damages or loss of critical license rights.
• Use of open source software may pose particular risks to proprietary software, products, and services.
• Ability to use net operating loss carryforwards and other tax attributes may be limited due to certain provisions of the Internal Revenue Code or state tax law.
• The effective tax rate may vary significantly from period to period due to various internal and external factors.
• Changes in tax laws or tax rulings could adversely affect effective tax rates, results of operations, and financial condition.
• The applicability of sales, use, and other tax laws or regulations on the business is uncertain, potentially leading to additional tax liability.
• Cash deposits with financial institutions exceed insured limits, posing a risk in the event of bank failure.
• Changes in accounting principles or their interpretation by FASB affecting consolidation of entities could impact the consolidation of total revenues derived from Physera Physical Therapy Group, PC (PPTG).

Future Outlook

The company expects to continue focusing on long-term growth of its core business while selectively investing in platform, programs, and operations. It anticipates increased operating expenses as a public company and believes current cash and cash equivalents will fund operations for at least the next 12 months. The company may seek additional financing through equity, equity-linked arrangements, or debt if needed. It also expects to expand managerial, clinical, scientific, technological, operational, finance, and other resources to manage future growth and will continue to invest in its virtual care platform. The rapidly evolving GLP-1 therapeutic space and AI regulatory landscape are key areas of focus and potential impact.

Management Comments

• Our mission is to bend the curve. Our hope is that, one day, tomorrows epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada.
• We strive to inspire and enable people to make lasting health changes on their own terms.
• We believe that our future growth, success, and performance are dependent on many factors.
• We expect to continue to focus on long-term growth of our core business, while selectively investing in areas that enhance our platform, programs, or operations.
• Though our focus remains on continued progress in our current care areas, we monitor the needs of our customers and channel partners, and we believe we are well positioned to respond to their requirements organically or, where appropriate, to add new capabilities through partnerships and potential acquisitions.
• We believe that our current cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months.
• We believe we are making progress toward achieving effectiveness of our internal control over financial reporting.

Industry Context

StockSavvy.ai notes that Omada Health operates in the rapidly expanding virtual care market, which is experiencing significant structural changes driven by rising healthcare costs and a shift towards patient-centric, personalized healthcare. The surge in GLP-1 adoption for obesity and weight management is a key industry trend, creating both opportunities for specialized companion programs and challenges related to balancing access with affordability for employers and health plans. The company's move into GLP-1 prescribing capabilities aligns with the evolving demand for integrated care models in this space. The increasing regulatory scrutiny on the healthcare industry, particularly regarding data privacy and AI technologies, presents a dynamic environment for all players.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings the outcome of which, if determined adversely, would individually or taken together, have a material adverse effect on its business, operating results, cash flows, or financial condition.

Related Party Transactions

• Affiliates of The Cigna Group (Partner A and Partner B), which beneficially own more than 5% of the company's outstanding capital stock, are significant customers and channel partners.
• Accounts receivable from related parties totaled $25.8 million as of March 31, 2026, and $22.8 million as of December 31, 2025.
• Prepaid expenses and other current assets from related parties totaled $0.5 million as of March 31, 2026, and $0.3 million as of December 31, 2025.
• Accrued expenses and other current liabilities from related parties totaled $6.9 million as of March 31, 2026, and $4.9 million as of December 31, 2025.
• Deferred revenue from related parties totaled $22.2 million as of March 31, 2026, and $18.8 million as of December 31, 2025.
• Services revenue from related parties was $46.0 million for the three months ended March 31, 2026, and $29.9 million for the three months ended March 31, 2025.
• Hardware revenue from related parties was $5.1 million for the three months ended March 31, 2026, and $3.4 million for the three months ended March 31, 2025.
• Payments from Cigna Group affiliates to the company totaled $48.3 million for the three months ended March 31, 2026, and $31.0 million for the three months ended March 31, 2025.
• Payments from the company to Cigna Group affiliates totaled $7.9 million for the three months ended March 31, 2026, and $4.8 million for the three months ended March 31, 2025.

Stakeholder Impact

• Shareholders: Strong revenue growth and reduced losses are positive, but potential future dilution from capital raises and stock price volatility remain risks. Management's Rule 10b5-1 plans indicate future stock sales by key executives.
• Employees: The company plans to increase headcount, including Care Teams, to support growth. New Executive Bonus Plan and amended Non-Employee Director Compensation Program aim to incentivize and retain talent. Risk of employee unionization is noted.
• Customers/Channel Partners: Increased revenue and a growing member base indicate strong demand for Omada's programs. However, significant reliance on a limited number of partners (Cigna affiliates) presents a concentration risk. The new GLP-1 prescribing capability could enhance offerings and customer value.
• Members: The company's programs, including new GLP-1 Care Tracks and prescribing offerings, are reaching a larger member base (over 1 million). Risks include potential member harm or injury from programs and dependence on third-party devices and connectivity.
• Creditors: The full repayment of outstanding debt facilities (MidCap) improves the company's financial position. However, the potential for future debt financing is mentioned if additional capital is required.

Next Steps

• Continue to focus on long-term growth of the core business.
• Selectively invest in areas that enhance the platform, programs, or operations.
• Monitor the needs of customers and channel partners to respond organically or through partnerships and potential acquisitions.
• Increase the size of the organization, including Care Teams, to support future growth.
• Continue efforts to remediate the material weakness in internal control over financial reporting.
• Evaluate the impact of new accounting standards (ASU 2024-03, ASU 2025-06, ASU 2025-11) on financial statement disclosures.
• Potentially engage in equity or debt financings if additional capital is required to support business growth and strategic initiatives.

Key Dates

Recommendation

Omada Health demonstrates impressive revenue growth and a substantial reduction in net loss, indicating strong operational improvements and market traction, particularly with its expanding member base and new GLP-1 offerings. However, the company remains unprofitable, faces intense competition in a rapidly evolving virtual care market, and is addressing a material weakness in internal controls. While the growth trajectory is positive, the inherent risks and the need for sustained profitability warrant a 'hold' recommendation for seasoned investors, suggesting continued monitoring of execution and risk mitigation.

Keywords

Virtual Care, Digital Health, Chronic Disease Management, Prediabetes, Diabetes, Hypertension, Musculoskeletal Conditions, GLP-1, Weight Management, Telehealth, Healthcare Technology, SEC Filing, 10-Q, Financial Results, Member Growth, Cigna, AI in Healthcare